Voyager Therapeutics Q1 Cash $171.7M Runway into 2028, $27.9M Loss
Voyager Therapeutics ended Q1 2026 with $171.7 million in cash and marketable securities, providing runway into 2028, and reported a net loss of $27.9 million. Collaboration revenue declined to $2.6 million while R&D expenses decreased to $24.6 million on cost-efficiency measures.
1. Financial Results
Voyager ended the quarter with $171.7 million in cash, cash equivalents and marketable securities, supporting operations into 2028. Collaboration revenue dropped to $2.6 million driven by maturation of Neurocrine and Novartis agreements. R&D expenses were $24.6 million, G&A $8.3 million, and net loss was $27.9 million.
2. Pipeline Progress
VY1706 tau silencing gene therapy completed IND-enabling GLP toxicology in Q1 and is on track for an FDA IND filing in Q2 2026, targeting first-in-human dosing in H2. VY7523 anti-tau antibody is slated to report tau PET imaging efficacy data in H2 from its multiple ascending dose trial.
3. Partnership and Presentations
Neurocrine completed GLP toxicology with NBIB-‘223 for Friedreich’s ataxia and secured FDA orphan drug designation, aiming for a clinical trial initiation in H2 pending IND clearance. Voyager has multiple abstracts accepted at ASGCT 2026, including a late-breaking oral on 3-month GLP tox data for VY1706.
4. Upcoming Milestones
Anticipated milestones include mid-2026 third-party tau knockdown data, H2 first-in-human dosing of VY1706, tau PET imaging results for VY7523, and Neurocrine’s trial start for NBIB-‘223 in Friedreich’s ataxia.